AstraZeneca Group (NYSE:AZN): Closing price $50.35
On Tuesday, the firm said that the United States District Court for the District of New Jersey ruled that its United States Patent No. 6,598,603, protecting Pulmicort Respules in the U.S., is invalid. Beyond that, the Court decided that the generic defendants involved in the litigation do not infringe AstraZeneca’s second patent, Patent No. 7,524,834. Executive Vice President, North America, Paul Hudson responed that “AstraZenca strongly disagrees with the Court’s decision. AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules. AstraZeneca is considering next steps, including an appeal of the Court’s decision.”
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.